COMMUNIQUÉS West-GlobeNewswire

NMDP Hires New Philanthropic Leader to Accelerate Financial Giving and Research
03/12/2025
MINNEAPOLIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- NMDP SM , a global nonprofit leader in cell therapy, hired Jessica Kowal as chief philanthropy officer to lead the NMDP Foundation SM , which expands access to blood stem [...]
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
03/12/2025
Prospective-trial analysis published in the Journal of the National Cancer Institute predicts residual cancer burden from baseline H&E slides using fully automated, treatment predictive platform NEWTON, Mass., Dec. [...]
MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell (MPC)-based Tissue-Engineered Therapy Showing Clinically Meaningful and Statistically Significant Benefits in Stress Urinary Incontinence
03/12/2025
Zurich, Switzerland, December 03, 2025 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 ( NCT05534269 ) evaluating its novel [...]
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
03/12/2025
STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Immuron New U.S. Department of Defense Award & Clinical Trial Update
03/12/2025
Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella Uniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 ( [...]
World Class Health Partners with GAM to Select and Directly Contract with Top Quality Surgeons
03/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- World Class Health (“WCH”), a global leader in medically led Centers of Excellence (CoE) networks, today announces their strategic partnership with Global Appropriateness [...]
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
03/12/2025
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours , significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of Progression™ 1 [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
03/12/2025
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an [...]
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
03/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino [...]
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
03/12/2025
Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at [...]
Microbix & Seegene Mexico Collaborate to Improve Test Accuracy
03/12/2025
Making HPV Tests & Quality Assessment Products Available across Mexico MISSISSAUGA, Ontario and MEXICO CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life [...]
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
03/12/2025
As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS). NRx has amended its [...]
Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline
03/12/2025
Deal with Laboratoires Th é a representing a total value of up to $280 million including clinical, regulatory and commercial conditional milestones, commercial royalties, and development responsibility for Phase 3 [...]
Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
03/12/2025
First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop CARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. ( [...]
Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader
03/12/2025
LRK-4189, which targets PIP4K2C, a key cancer cell fitness target, is being developed for microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors Clinical study begins with healthy participants to [...]
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
03/12/2025
Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals [...]
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
03/12/2025
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, [...]
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
03/12/2025
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release [...]
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
03/12/2025
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January - PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ [...]

Pages